title: Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
authors.affiliation: Bone Strategy, Eli Lilly, Australia.
authors.forename: Daniel
authors.initials: D
authors.lastname: Thiebaud
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control; D019379:Teriparatide / Q000627:therapeutic use; D035703:Therapies, Investigational; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004965:Estrogen Antagonists; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide; D020849:Raloxifene Hydrochloride